UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study

Pediatric blood & cancer, 2021-10, Vol.68 (10), p.e29117

2021

Volltextzugriff (PDF)

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

Seminars in nuclear medicine, 2016-05, Vol.46 (3), p.203-214

2016

Volltextzugriff (PDF)

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Clinical cancer research, 2022-09, Vol.28 (18), p.4146-4157

2022

Volltextzugriff (PDF)

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4162-4168

2009

Volltextzugriff (PDF)

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

Annals of nuclear medicine, 2024-07, Vol.38 (7), p.553-562

2024

Volltextzugriff (PDF)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma

Endocrine-related cancer, 2023-02, Vol.30 (2), p.1

2023

Volltextzugriff (PDF)

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation

European journal of nuclear medicine and molecular imaging, 2022-04, Vol.49 (5), p.1574-1583

2022

Volltextzugriff (PDF)

Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma

Journal of clinical oncology, 2007-03, Vol.25 (9), p.1054-1060

2007

Volltextzugriff (PDF)

Nurses' Experiences Caring for Children With Neuroblastoma Receiving 131 I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study

Journal of pediatric hematology/oncology nursing, 2023-03, Vol.40 (2), p.82-90

2023

Volltextzugriff (PDF)

A model for in situ plan of care for a critically unstable pediatric patient following I‐131 MIBG infusion

Pediatric blood & cancer, 2020-11, Vol.67 (11), p.e28665-n/a

2020

Volltextzugriff (PDF)

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

Journal of clinical oncology, 2009-03, Vol.27 (7), p.1020-1025

2009

Volltextzugriff (PDF)

Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine

Annals of nuclear medicine, 2015-07, Vol.29 (6), p.543-552

2015

Volltextzugriff (PDF)

Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Journal of Nuclear Medicine, 2019-05, Vol.60 (5), p.623-630

2019

Volltextzugriff (PDF)

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine

European journal of cancer (1990), 2016-10, Vol.66, p.144-152

2016

Volltextzugriff (PDF)

Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults

Cancer, 2011-09, Vol.117 (18), p.4286-4293

2011

Volltextzugriff (PDF)

Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

Journal of clinical oncology, 2006-01, Vol.24 (3), p.500-506

2006

Volltextzugriff (PDF)

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma

Cochrane database of systematic reviews, 2017-04, Vol.4 (4), p.CD010349

2017

Volltextzugriff (PDF)

Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131 I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma

International journal of radiation oncology, biology, physics, 2023-04, Vol.115 (5), p.1115

2023

Volltextzugriff (PDF)

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

The Journal of nuclear medicine (1978), 2016-02, Vol.57 (2), p.231-237

2016

Volltextzugriff (PDF)

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

Nuclear medicine and biology, 2008-08, Vol.35 (Suppl 1), p.S35-S48

2008

Volltextzugriff (PDF)

Primary Ovarian Insufficiency in Children After Treatment With 131I-Metaiodobenzylguanidine for Neuroblastoma: Report of the First Two Cases

The journal of clinical endocrinology and metabolism, 2014-01, Vol.99 (1), p.E112-E116

2014

Volltextzugriff (PDF)

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

Annals of nuclear medicine, 2022-03, Vol.36 (3), p.267-278

2022

Volltextzugriff (PDF)

A comparison of thyroid blockade strategies in paediatric 123I-meta-iodobenzylguanidine scanning: a dual centre study

Nuclear medicine communications, 2020-05, Vol.41 (5), p.436-442

2020

Volltextzugriff (PDF)

Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre

QJM : An International Journal of Medicine, 2015-05, Vol.108 (5), p.361-368

2015

Volltextzugriff (PDF)

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.468-475

2017

Volltextzugriff (PDF)

1 – 25 von 220

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(163)

Publikationsform

Artikel
(220)

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(215)
Male
(139)
Female
(135)
Life Sciences & Biomedicine
(111)
Science & Technology
(111)
3-Iodobenzylguanidine
(102)
3-Iodobenzylguanidine - Adverse Effects
(100)
Adult
(84)
Child
(81)
Middle Aged
(80)
3-Iodobenzylguanidine - Therapeutic Use
(69)
Aged
(63)
Neuroblastoma - Radiotherapy
(63)
Adolescent
(58)
Child, Preschool
(58)
Radionuclide Imaging
(56)
Radiopharmaceuticals - Adverse Effects
(53)
Iodine Radioisotopes - Therapeutic Use
(50)
Radiology, Nuclear Medicine & Medical Imaging
(48)
Biological And Medical Sciences
(45)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation

Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma

Nurses' Experiences Caring for Children With Neuroblastoma Receiving 131 I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study

A model for in situ plan of care for a critically unstable pediatric patient following I‐131 MIBG infusion

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine

Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine

Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults

Phase I Dose Escalation of Iodine-131–Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma

Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131 I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

Primary Ovarian Insufficiency in Children After Treatment With 131I-Metaiodobenzylguanidine for Neuroblastoma: Report of the First Two Cases

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

A comparison of thyroid blockade strategies in paediatric 123I-meta-iodobenzylguanidine scanning: a dual centre study

Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma

Suchergebnisse filtern